Autologous cytomegalovirus‐specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia

Summary B‐cell chronic lymphocytic leukaemia (B‐CLL) cells express low levels of co‐stimulatory molecules and therefore fail to induce activation and differentiation of tumour‐specific T cells. We have shown that patients with B‐CLL have considerably expanded numbers of cytomegalovirus (CMV) reactiv...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2004-08, Vol.126 (4), p.512-516
Main Authors: Kater, Arnon P., Remmerswaal, Ester B. M., Nolte, Martijn A., Eldering, Eric, Van Oers, Marinus H. J., Van Lier, René A. W.
Format: Article
Language:English
Subjects:
Biological and medical sciences
B‐CLL
Cell Division - immunology
CMV
Cytomegalovirus - immunology
Cytotoxicity, Immunologic
Hematologic and hematopoietic diseases
Hematology
Humans
immunotherapy
Immunotherapy - methods
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphocyte Activation - immunology
Medical sciences
T-Lymphocytes, Cytotoxic - immunology
Tumor Cells, Cultured
virus specific CD8+ cell
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary B‐cell chronic lymphocytic leukaemia (B‐CLL) cells express low levels of co‐stimulatory molecules and therefore fail to induce activation and differentiation of tumour‐specific T cells. We have shown that patients with B‐CLL have considerably expanded numbers of cytomegalovirus (CMV) reactive CD8+ T cells. This study demonstrated that B‐CLL cells loaded with CMV peptide not only promoted the ex vivo expansion of autologous, in vivo‐generated virus‐specific T cells, but also constituted excellent target cells for these cytotoxic Tcells, even without ex vivo re‐stimulation. Directing virus‐specific T cells to B‐CLL may overcome the inadequate immunostimulatory capacity of these cells, which could be exploited for T‐cell mediated immunotherapy.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2004.05070.x